NYSE : DNA
Ginkgo Bioworks Holdings, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 11.21 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 754.88M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 754.88M |
| Enterprise Value | 856.83M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 55.38M |
| Shares Outstanding | 67.34M |
| Shares Change (YoY) | +8.92% |
| Shares Change (QoQ) | +4.25% |
| Owned by Insiders (%) | 14.73% |
| Owned by Institutions (%) | 53.43% |
| Float | 50.03M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.70 |
| Forward PS | 8.17 |
| PB Ratio | 1.70 |
| P/TBV Ratio | 2.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 6.47 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.57 |
| Quick Ratio | 4.33 |
| Debt / Equity | 0.96 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -59.94% |
| Return on Assets (ROA) | -16.72% |
| Return on Invested Capital (ROIC) | -19.90% |
| Return on Capital Employed (ROCE) | -32.38% |
| Weighted Average Cost of Capital (WACC) | 9.20% |
| Revenue Per Employee | $273,033 |
| Profits Per Employee | -$599,594 |
| Employee Count | 485 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -594,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.79 |
| 52-Week Price Change | -8.04% |
| 50-Day Moving Average | 9.55 |
| 200-Day Moving Average | 8.59 |
| Relative Strength Index (RSI) | 51.97 |
| Average Volume (20 Days) | 3,511,400 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.29M |
| Short Previous Month | 7.17M |
| Short % of Shares Out | 12.32% |
| Short % of Float | 16.58% |
| Short Ratio (days to cover) | 2.40 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 132.42M |
| Gross Profit | 90.10M |
| Operating Income | -297.06M |
| Pretax Income | -310.23M |
| Net Income | -290.80M |
| EBITDA | -261.63M |
| EBIT | -297.06M |
| Loss Per Share | -$4.96 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 302.16M |
| Total Debt | 404.11M |
| Net Cash | -101.95M |
| Net Cash Per Share | -$1.51 |
| Equity (Book Value) | 420.28M |
| Book Value Per Share | 6.60 |
| Working Capital | 259.80M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -170.24M |
| Capital Expenditures | -4.56M |
| Depreciation & Amortization | 35.43M |
| Net Borrowing | -68,000 |
| Free Cash Flow | -174.80M |
| FCF Per Share | -$2.60 |
Margins
| Measure | Value |
|---|
| Gross Margin | 68.04% |
| Operating Margin | -224.33% |
| Pretax Margin | -234.28% |
| Profit Margin | -219.60% |
| EBITDA Margin | -197.57% |
| EBIT Margin | -224.33% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.92% |
| Shareholder Yield | -8.92% |
| Earnings Yield | -44.27% |
| FCF Yield | -23.16% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.00 |
| Price Target Difference | -28.64% |
| Analyst Consensus | Sell |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 20.32% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -8.82 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |